1. World Health Organization. WHO Global Tuberculosis Report Executive Summary 2018 [Internet]. 2018. Available from: http://www.who.int/tb/publications/global_report/tb18_ExecSum_web_4Oct18.pdf
2. WHO. Guidelines for Treatment of Tuberculosis and Patient Care [Internet]. Vol. 1, Who. 2017. 85-97 p. Available from: http://www.tandfonline.com/doi/full/10.1586/17476348.1.1.85
3. Kisambu J, Nuwaha F, Sekandi JN. Adherence to treatment and supervision for tuberculosis in a DOTS programme among pastoralists in Uganda. Int J Tuberc Lung Dis. 2014;18(7):799–803.
4. Kaona FAD, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health. 2004;4:1–8.
5. Kebede A, Wabe NT. Medication adherence and its determinants among patients on concomitant tuberculosis and antiretroviral therapy in south west Ethiopia. N Am J Med Sci. 2012;4(2):67–71.
6. Woimo TT, Yimer WK, Bati T, Gesesew HA. The prevalence and factors associated for anti-tuberculosis treatment non-adherence among pulmonary tuberculosis patients in public health care facilities in South Ethiopia: a cross-sectional study. BMC Public Health. 2017;17(1):1–10.
7. van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: A pilot study. Bull World Health Organ. 2011;89(9):632–9.
8. Kidenya BR, Mshana SE, Gerwing-Adima L, Kidola J, Kasang C. Drug adherence and efficacy of smear microscopy in the diagnosis of pulmonary tuberculosis after 2 months of medication in North-western Tanzania. Int J Infect Dis [Internet]. 2017;63:43–7. Available from: http://dx.doi.org/10.1016/j.ijid.2017.07.025
9. World Health Organization. Tuberculosis country factsheet: United Republic of Tanzania [Internet]. 2018. Available from: http://books.google.com/books?hl=en&lr=&id=VO8K9h9GvaoC&oi=fnd&pg=PA33&dq=United+Republic+of+TANZANIA&ots=C4i8jUhKWP&sig=n71vkxuuigvBX2FbecnoPyBkKGY
10. Van Den Boogaard J, Lyimo R, Irongo CF, Boeree MJ, Schaalma H, Aarnoutse RE, et al. Community vs. facility-based directly observed treatment for tuberculosis in Tanzania’s Kilimanjaro Region. Int J Tuberc Lung Dis. 2009;13(12):1524–9.
11. Van den Boogaard J, Boeree MJ, Kibiki GS, Aarnoutse RE. The complexity of the adherence-response relationship in tuberculosis treatment: Why are we still in the dark and how can we get out? Trop Med Int Heal. 2011;16(6):693–8.
12. Adane AA, Alene KA, Koye DN, Zeleke BM. Non-adherence to anti-tuberculosis treatment and determinant factors among patients with tuberculosis in northwest Ethiopia. PLoS One. 2013;8(11).
13. Habteyes Hailu Tola1, 2*, Gholamreza Garmaroudi1, Davoud Shojaeizadeh1, Azar Tol1, Mir Saeed Yekaninejad3, Luche Tadesse Ejeta1, Abebaw Kebede2 DK. The Effect of Psychosocial Factors and Patient s ’ Perception of Tuberculosis Treatment Non-Adherence in Addis Ababa , Ethiopia. Ethiop J Heal Sci. 2017;27(5):447–58.
14. Gebreweld FH, Kifle MM, Gebremicheal FE, Simel LL, Gezae MM, Ghebreyesus SS, et al. Factors influencing adherence to tuberculosis treatment in Asmara, Eritrea: a qualitative study. J Heal Popul Nutr [Internet]. 2018;37(1):1. Available from: https://jhpn.biomedcentral.com/articles/10.1186/s41043-017-0132-y
15. Méda ZC, Lin YT, Sombié I, Maré D, Morisky DE, Chen YMA. Medication-adherence predictors among patients with tuberculosis or human immunodeficiency virus infection in Burkina Faso. J Microbiol Immunol Infect. 2014;47(3):222–32.
16. Ali AOA, Prins MH. Patient non adherence to tuberculosis treatment in Sudan: Socio demographic factors influencing non adherence to tuberculosis therapy in Khartoum State. Pan Afr Med J. 2016;25:1–11.
17. Dick J LC. Shared vision - a health education project designed to enhance adherence to anti-tuberculosis treatment. Int J Tuberc Lung Dis. 1997;1(2):181–6.
18. Liefooghe R, Suetens C, Meulemans H, Moran MB, De Muynck A. A randomised trial of the impact of counselling on treatment adherence of tuberculosis patients in Sialkot, Pakistan. Int J Tuberc Lung Dis. 1999;3(12):1073–80.
19. Nhavoto JA, Gronlun A, Klein GO. Mobile health treatment support intervention for HIV and tuberculosis in Mozambique : Perspectives of patients and healthcare workers. PLoS One. 2017;1–13.
20. Bediang G, Stoll B, Elia N, Abena JL, Nolna D, Chastonay P, et al. SMS reminders to improve the tuberculosis cure rate in developing countries (TB-SMS Cameroon): A protocol of a randomised control study. Trials. 2014;15(1):1–9.
21. Mesfin MM, Newell JN, Walley JD, Gessessew A, Tesfaye T, Lemma F, et al. Quality of tuberculosis care and its association with patient adherence to treatment in eight Ethiopian districts. Health Policy Plan. 2009;24(6):457–66.
22. Jaiswal A, Singh V, Ogden JA, Porter JDH, Sharma PP, Sarin R, et al. Adherence to tuberculosis treatment: Lessons from the urban setting of Delhi, India. Trop Med Int Heal. 2003;8(7):625–33.
23. Sagbakken M, Frich JC, Bjune G. Barriers and enablers in the management of tuberculosis treatment in Addis Ababa, Ethiopia: A qualitative study. BMC Public Health. 2008;8:1–11.
24. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Heal Promot. 1997;12(1):38–48.
25. Willey C(1), Redding C, Stafford J, Garfield F, Geletko S, Flanigan T M, K, Mitty J CJ. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther. 2000;22(7):858–71.
26. Kavookjian J, Berger BA, Grimley DM, Villaume WA, Anderson HM, Barker KN. Patient decision making: Strategies for diabetes diet adherence intervention. Res Soc Adm Pharm. 2005;1(3):389–407.
27. Liu Q, Abba K, Alejandria MM, Sinclair D, Balanag VM, Lansang MAD. Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment. Cochrane Database Syst Rev. 2014;2014(11).
28. Marcolino MS, Oliveira JAQ, D’Agostino M, Ribeiro AL, Alkmim MBM, Novillo-Ortiz D. The Impact of mHealth Interventions: Systematic Review of Systematic Reviews. JMIR mHealth uHealth [Internet]. 2018;6(1):e23. Available from: http://mhealth.jmir.org/2018/1/e23/
29. Nglazi MD, Bekker L-G, Wood R, Hussey GD, Wiysonge CS. Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review protocol. Syst Rev [Internet]. 2013;2(1):6. Available from: http://systematicreviewsjournal.biomedcentral.com/articles/10.1186/2046-4053-2-6
30. Ngwatu BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, Nguyen NL, Jaramillo E, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J [Internet]. 2018;51(1):1701596. Available from: http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01596-2017
31. Tanzania Communications Regulatory Authority. Quarterly Communications Statistics Report. 2017;(December). Available from: https://www.tcra.go.tz/images/documents/telecommunication/TelCom_Statistics_Dec_2017.pdf
32. Hirsch-Moverman Y, Daftary A, Yuengling KA, Saito S, Ntoane M, Frederix K, et al. Using mHealth for HIV/TB Treatment Support in Lesotho. JAIDS J Acquir Immune Defic Syndr [Internet]. 2017;74:S37–43. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00126334-201701011-00006
33. Lei X, Liu Q, Wang H, Tang X, Li L, Wang Y. Is the short messaging service feasible to improve adherence to tuberculosis care? A cross-sectional study. Trans R Soc Trop Med Hyg. 2013;107(10):666–8.
34. Bediang G, Stoll B, Elia N, Abena J-L, Geissbuhler A. SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): a randomised controlled trial. BMC Public Health [Internet]. 2018;18(1):583. Available from: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-018-5502-x
35. Hermans SM, Elbireer S, Tibakabikoba H, Hoefman BJ, Manabe YC. Text messaging to decrease tuberculosis treatment attrition in TB-HIV coinfection in Uganda. Patient Prefer Adherence. 2017;11:1479–87.
36. Mohammed S, Glennerster R, Khan AJ. Impact of a Daily SMS Medication Reminder System on Tuberculosis Treatment Outcomes : A Randomized Controlled Trial. 2016;1–14.
37. Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. PLoS Med. 2015;12(9):1–18.
38. Abdulrahman SA, Rampal L, Ibrahim F, Radhakrishnan AP, Shahar HK, Othman N. Mobile phone reminders and peer counseling improve adherence and treatment outcomes of patients on ART in Malaysia: A randomized clinical trial. PLoS One. 2017;12(5):1–16.
39. Fang X-H, Guan S-Y, Tang L, Tao F-B, Zou Z, Wang J-X, et al. Effect of Short Message Service on Management of Pulmonary Tuberculosis Patients in Anhui Province, China: A Prospective, Randomized, Controlled Study. Med Sci Monit [Internet]. 2017;23:2465–9. Available from: http://www.medscimonit.com/abstract/index/idArt/904957
40. Subbaraman R, Mayer K, Muslimenta A, Thomas B. Digital adherence technologies for the treatment of tuberculosis: landscape and research priorities. BMJ Glob Heal. 2018;3:1–16.
41. Nsengiyumva NP, Mappin-Kasirer B, Oxlade O, Bastos M, Trajman A, Falzon D, et al. Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support. Eur Respir J [Internet]. 2018;1801363. Available from: http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01363-2018
42. Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico KR, Friedland G, et al. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infect Dis. 2018;18(1):1–9.
43. Sumari-de Boer IM, van den Boogaard J, Ngowi KM, Semvua HH, Kiwango KW, Aarnoutse RE, et al. Feasibility of Real Time Medication Monitoring Among HIV Infected and TB Patients in a Resource-Limited Setting. AIDS Behav. 2016;20(5):1097–107.
44. Liu X, Blaschke T, Thomas B, De Geest S, Jiang S, Gao Y, et al. Usability of a medication event reminder monitor system (MERM) by providers and patients to improve adherence in the management of tuberculosis. Int J Environ Res Public Health. 2017;14(10):1–11.
45. Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–6.
46. DeSilva MB, Gifford AL, Xu K, Li Z, Feng C, Brooks M, et al. Feasibility and acceptability of a real-time adherence device among HIV-positive IDU patients in China. (Special Issue: Using mobile health technology to improve HIV care for persons living with HIV and substance abuse.). AIDS Res Treat. 2013;957862(16).
47. Sabin LL, DeSilva MB, Gill CJ, Li Z. Improving Adherence to Antiretroviral Therapy with Triggered Real Time Text Message Reminders: the China through Technology Study (CATS). J Acquir Immune Defic Syndr. 2015;69(5):551–559.
48. Stop TB Partnership. TB Medication Adherence & Treatment Outcomes. Vol. 3. 2017.
49. National Tuberculosis and Leprosy Programme. Tuberculosis data from Kilimanjaro, Tanzania. 2017.
50. World Health Organization. United Republic of Tanzania: Tuberculosis profile. 2016; Available from: https://extranet.who.int/sree/Reports?op=Replet&name=/WHO_HQ_Reports/G2/PROD/EXT/TBCountryProfile&ISO2=TZ&outtype=PDF
51. Van Rie A, Sengupta S, Pungrassami P, Balthip Q, Choonuan S, Kasetjaroen Y, et al. Measuring stigma associated with tuberculosis and HIV/AIDS in southern Thailand: Exploratory and confirmatory factor analyses of two new scales. Trop Med Int Heal. 2008;13(1):21–30.
52. Baron RM K DA. The Moderator-Mediator Variable Distinction in Social Psychological Research: Conceptual, Strategic, and Statistical Considerations. J Pers Soc Psych [Internet]. 1986;51(6):1173–82. Available from: http://gradworks.umi.com/36/37/3637300.html%5Cnhttp://gradworks.umi.com/3637300.pdf%0Ahttp://trn.sagepub.com/cgi/doi/10.1177/0265378809103384%0Ahttp://www.regent.edu/acad/global/publications/ijls/new/vol6iss1/1_Final Edited Vondey_pp3-27.pdf%0Ahttp://hci2
53. Hassard S, Ronald A, Angella K. Patient attitudes towards community-based tuberculosis DOT and adherence to treatment in an urban setting; Kampala, Uganda. Pan Afr Med J. 2017;27:1–6.
54. Kipp AM, Pungrassami P, Stewart PW, Chongsuvivatwong V, Strauss RP, Van Rie A. Study of tuberculosis and AIDS stigma as barriers to tuberculosis treatment adherence using validated stigma scales. Int J Tuberc Lung Dis. 2011;15(11):1540–5.
55. Chowdhury MRK, Rahman MS, Mondal MNI, Sayem A, Billah B. Social impact of stigma regarding tuberculosis hindering adherence to treatment: A cross sectional study involving tuberculosis patients in Rajshahi City, Bangladesh. Jpn J Infect Dis. 2015;68(6):461–6.
56. Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol. 2005;45(4):461–7.